Kathleen Moore to Thrombocytopenia
This is a "connection" page, showing publications Kathleen Moore has written about Thrombocytopenia.
Connection Strength
0.305
-
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
Score: 0.139
-
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
Score: 0.125
-
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021 Feb; 8(2):e122-e134.
Score: 0.041